Cingulate Inc. Warrants (CINGW)

About CINGW

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

14

Fundamentals

1-day range

$0.004$0.0087

Market cap

$133.3K

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

—

Dividend yield

—

Beta

0.59

Avg. volume

—

Cingulate Inc. Warrants Competitors

Chosen by industry and closest market cap.

• CINGW

  Cingulate Inc. Warrants

  $0.01

  ▲ 14.94%
  Market cap $133.3KP/E —
  $0.0026$0.12
• ERNAW

  Ernexa Therapeutics Inc. Warrants

  $0.0253

  ▼ 9.96%
  Market cap $52.4KP/E —
  $0.0213$0.2278
• CDTTW

  CDT Equity Inc. Warrant

  $0.0074

  ▲ 21.31%
  Market cap $9.3KP/E —
  $0.002$0.02
• BFRIW

  Biofrontera Inc. Warrants

  $0.0052

  ▼ 7.14%
  Market cap $357.2KP/E —
  $0.0052$0.1484
• BIVIW

  BioVie Inc. Warrant

  $0.2301

  ▼ 7.96%
  Market cap $1.06MP/E —
  $0.13$0.79
• BDRX

  Biodexa Pharmaceuticals plc American Depositary Shs

  $0.456

  ▲ 5.80%
  Market cap $1.10MP/E —
  $0.3371$44.7
• MTNB

  Matinas Biopharma Holdings Inc. Common Stock

  $2.37

  ▼ 2.07%
  Market cap $1.72MP/E —
  $2.26$28.95

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

30.3K

Total value held

$917

Institutional holders

4